US-Israeli startup Theator uses computer vision and machine learning algorithms to help surgeons prepare for procedures by reviewing previous cases. Its Minute system edits videos of surgical procedures to highlight the key steps and “outcome-critical” components to reduce medical errors.
Dravet syndrome is an epileptic condition with a 15 to 20 percent mortality rate and resistant to current medications. Tel Aviv University researchers have discovered that the DHODH gene is key to triggering such adverse neural activity and that Terflunomide can inhibit it.
Tel Aviv University scientists have linked gene Gtf2i to Williams Syndrome (WS) and the thinning of the myelin layer that protects neurons in the brain. In lab tests they managed to reverse some WS symptoms using the FDA-approved antihistamine clemastine fumarate.
I reported previously on Israel’s Betalin Therapeutics, which has developed an insulin-producing micro pancreas that can be implanted into the body of diabetics. Betalin has since won startup awards in Tel Aviv and China and has just raised funds to help start human trials this year.
The US FDA has approved the generic naloxone hydrochloride nasal spray developed by Israel’s Teva. Commonly known as Narcan, the medication can stop or reverse the effects of an opioid overdose. The emergency treatment can be administered even by those without medical training.
I reported previously (see here) on the NeuroAD cranial device from Israel’s Neuronix. It already has European approval and is now being urgently reviewed in the FDA’s Expedited Access Pathway program for breakthrough devices that target vital unmet needs.
I reported previously on Israel’s Sight Diagnostics’ device that can perform full blood tests using just a few drops of blood. Sight Diagnostics has just completed a successful trial which should help it obtain US FDA approval. The device is already marketed in Europe and Israel.
I reported previously when retired surgeon Norman Rosenbaum was awarded by UK PM Theresa May for helping to buy 11 ambulances for Israeli emergency service Magen David Adom. Norman has just fundraised his 12th ambulance for MDA who awarded him Humanitarian of the Year.
A recent study of Go-Less Men (EFLA940 - an extract from pumpkin seeds) to be effective in the treatment of symptoms of BHP (Benign Prostatic Hyperplasia). Go-Less is marketed by Israel-founded Frutarom. A previous study showed Go-Less to relieve incontinence in women.
At Israel’s Weizmann Institute there are over 60 research groups focusing on beating cancer and over 40% of the Institute’s life sciences research is cancer-related.